A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02819323
Recruitment Status : Completed
First Posted : June 30, 2016
Last Update Posted : April 9, 2018
Information provided by (Responsible Party):
Braintree Laboratories

Brief Summary:
The objective of this study is to compare the safety, tolerance and efficacy of BLI800 to a PEG based preparation prior to colonoscopy in adolescent patients.

Condition or disease Intervention/treatment Phase
Colonoscopy Drug: PEG-ELS Drug: BLI800 Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 99 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy
Study Start Date : June 2016
Actual Primary Completion Date : March 27, 2018
Actual Study Completion Date : March 27, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Colonoscopy

Arm Intervention/treatment
Experimental: BLI800 high dose
BLI800 bowel preparation (high dose)
Drug: BLI800
BLI800 bowel preparation

Experimental: BLI800 low dose
BLI800 bowel preparation (low dose)
Drug: BLI800
BLI800 bowel preparation

Active Comparator: PEG-ELS
PEG based bowel preparation
polyethylene glycol based bowel preparation

Primary Outcome Measures :
  1. % of subjects with successful bowel cleansing [ Time Frame: 2 days ]
    Cleansing is rated by a blinded colonoscopist on a 4 point scale (1=poor to 4 = excellent)

Secondary Outcome Measures :
  1. Change in serum chemistry parameters [ Time Frame: up to 30 days ]
    Change in serum chemistry parameters from baseline to each follow up time point

  2. % of subjects with treatment emergent adverse events [ Time Frame: up to 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female between the ages of 12 to 16 (inclusive)
  2. Undergoing colonoscopy for routinely accepted indications, including (but not limited to):

    • Subjected inflammatory bowel disease (IBD) or IBD follow-up
    • Lower gastrointestinal bleeding
    • Suspected colitis (allergic or other)
    • Abdominal pain
    • Chronic diarrhea
    • Cancer surveillance
    • Anemia of unknown etiology
    • Abnormal endosonography or manometry
    • Evaluation of barium enema results
  3. If female, and of child-bearing potential, subject must use an acceptable form of birth control or remain abstinent for the duration of the study.
  4. Negative pregnancy test at screening, if applicable
  5. In the Investigator's judgment, caregiver is mentally competent to provide informed consent for their child to participate in the study.

Exclusion Criteria:

  1. Subjects with known or suspected ileus, impaction, severe ulcerative colitis, acute peritonitis, gastrointestinal obstruction, gastric retention (gastroparesis), bowel perforation, toxic colitis or megacolon.
  2. Subjects who had previous significant gastrointestinal surgeries.
  3. Subjects with increased risk of bowel perforation, including connective tissue disorders, toxic dilation of the bowel or recent bowel surgery.
  4. Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results, such as hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia, uncorrected dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.
  5. Subjects with bleeding disorders and/or impaired platelet function, or neutropenia.
  6. Subjects with a prior history of renal, liver or cardiac insufficiency (including congestive heart failure or other significant cardiac abnormality)
  7. Subjects with estimated glomerular filtration rate (GFR) below normal range (less than 70 ml/min/1.73m2)
  8. Subjects required to take any other oral medication within 3 hours of dosing until completion of both doses.
  9. Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  10. Subjects with tendency for nausea and/or vomiting, or that have known swallowing disorders.
  11. Subjects for whom intake of substances is likely to affect gastrointestinal motility or urinary flow rate.
  12. Subjects undergoing colonoscopy for foreign body removal and/or decompression.
  13. Subjects with an abnormal ECG result at Visit 1.
  14. Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  15. Subjects of childbearing potential who refuse a pregnancy test.
  16. Subjects with a history of hypersensitivity to any preparation components.
  17. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures and history of major medical/psychiatric conditions that would compromise the safety of the study.
  18. Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.
  19. Subjects who withdraw consent before completion of Visit 1 procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02819323

  Hide Study Locations
United States, Alabama
Braintree Research Site 27
Mobile, Alabama, United States, 36582
United States, Arizona
Braintree Research Site 30
Tucson, Arizona, United States, 85724
United States, California
Braintree Research Site 23
Orange, California, United States, 92868
Braintree Research Site 16
San Francisco, California, United States, 94158
United States, Florida
Braintree Research Site 5
Gainesville, Florida, United States, 32610
Braintree Research Site 24
Jacksonville, Florida, United States, 32207
Braintree Research Site 21
Orlando, Florida, United States, 32806
United States, Georgia
Braintree Research Site 2
Atlanta, Georgia, United States, 30342
United States, Illinois
Braintree Research Site 13
Chicago, Illinois, United States, 60611
Braintree Research Site 3
Park Ridge, Illinois, United States, 60068
United States, Indiana
Braintree Research Site 26
Indianapolis, Indiana, United States, 46202
United States, Minnesota
Braintree Research Site 25
Minneapolis, Minnesota, United States, 55454
Braintree Research Site 18
Rochester, Minnesota, United States, 55905
United States, Mississippi
Braintree Research Site 1
Flowood, Mississippi, United States, 39232
United States, New York
Braintree Research Site 32
Bronx, New York, United States, 10467
Braintree Research Site 9
Buffalo, New York, United States, 14222
Braintree Research Site 28
New York, New York, United States, 10021
Braintree Research Site 19
New York, New York, United States, 10032
United States, Pennsylvania
Braintree Research Site 6
Pittsburgh, Pennsylvania, United States, 15224
United States, Tennessee
Braintree Research Site 20
Memphis, Tennessee, United States, 38103
United States, Texas
Braintree Research Site 34
Plano, Texas, United States, 75093
United States, Utah
Braintree Research Site 22
Salt Lake City, Utah, United States, 84118
United States, Vermont
Braintree Research Site 10
Burlington, Vermont, United States, 05401
United States, Virginia
Braintree Research Site 17
Norfolk, Virginia, United States, 23507
Braintree Research Site 4
Roanoke, Virginia, United States, 24013
United States, Washington
Braintree Research Site 11
Seattle, Washington, United States, 98105
United States, Wisconsin
Braintree Research Site 14
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Braintree Laboratories
Study Director: John McGowan Braintree Laboratories, Inc.

Responsible Party: Braintree Laboratories Identifier: NCT02819323     History of Changes
Other Study ID Numbers: BLI800-502
First Posted: June 30, 2016    Key Record Dates
Last Update Posted: April 9, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No